Infectious DiseaseGI / Hepatology
Hepatitis B / C — Screening & Management
Risk-based screening, distinguish acute / chronic, antiviral therapy, HCC surveillance.
Source: BASL 2024; EASL; NICE NG161
Step 1 of ~4
question
Hepatitis B or C?
Different management.
Related
Curated clinical cross-links plus same-class fallbacks.
Drugs
- Entecavir · Antiviral — Hepatitis B (Nucleoside Analogue)
- Tenofovir (TDF/TAF) · Antiviral — Hepatitis B (Nucleotide Analogue)
- Glecaprevir / Pibrentasvir · Antiviral — Hepatitis C (Pan-Genotypic DAA)
- Sofosbuvir / Velpatasvir · Antiviral — Hepatitis C (Pan-Genotypic DAA)
- Remdesivir · Antiviral — RNA Polymerase Inhibitor (COVID-19 / Hepatitis)
- Insulin (IV Infusion — ICU Glucose Control) · Insulin — ICU Glucose Management
Pathways
- Infective Endocarditis · ESC 2023 Infective Endocarditis Guidelines; NICE NG41
- Eczema Herpeticum · BAD; NICE CKS
- Suspected Bacterial Meningitis (Adult) · NICE NG240 (2024); NICE NG143 (paeds)
- Clostridioides difficile Colitis · NICE NG199 (2021); IDSA/SHEA 2021
- Returning Traveller — Fever · NaTHNaC; PHE; ESCMID 2018
- Malaria — Diagnosis & Management · PHE 2016; WHO 2023
Decision support only. Always apply local guidelines and clinical judgement.